| Description | S728-1157 is a broadly neutralizing antibody (bnAb) targeting the receptor-binding site (RBS) that is fully exposed when the RBD on the spike is in the up conformation. S728-1157 showed high neutralization potency against D614G and cross-neutralized Beta, Delta, Kappa, Mu, and Omicron BA.1. S728-1157 can reduced WT, Delta, and BA.1 viral replication in vivo. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 (D614G, Beta, Delta, Kappa, Mu, and Omicron BA.1/BA.2/BA.2.75/BA.4/BA.5/BL.1/XBB) |
| Epitope | S728-1157 bound the RBS-A epitope in the RBD-up conformation. |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | In ELISA assay, the antibody started at 10 μg/mL with a serial 1:3 dilution. The neutralizing ability of the antibody against BA.2.75, BL.1, BA.4, BA.5, and XBB was measured by Neutralization assay with an IC50 value of 8-300 ng/mL. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
